Form 4: Estrella Immunopharma CEO Awarded Stock Options
SEC Form 4
Estrella Immunopharma's CEO, Cheng Liu, received incentive and nonstatutory share options totaling 1,000,000 shares on October 30, 2024.
Summary
- Cheng Liu, CEO of Estrella Immunopharma, was granted incentive and nonstatutory share options on October 30, 2024.
- The incentive share option grant was for 490,796 shares.
- The nonstatutory share option grant was for 509,204 shares.
- Both options have an exercise price of $0.815.
- 25% of each option grant is immediately exercisable, with the remaining 75% vesting in equal monthly installments over the subsequent 36 months.
Sentiment
Score: 7
Explanation: The granting of stock options is generally viewed positively as it aligns management's interests with shareholders. The vesting schedule promotes long-term commitment.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Stakeholder Impact
- Shareholders may view the stock option grants positively as they incentivize the CEO to increase the company's value.
- Employees may be motivated by the fact that the CEO is incentivized to improve the company's performance.
Key Dates
| Date | Description |
|---|---|
| 10/30/2024 | Date of the incentive and nonstatutory share option grants to Cheng Liu. |
| 10/31/2024 | Date from which the vesting schedule begins for both option grants. |
| 10/29/2034 | Expiration date for both the incentive and nonstatutory share options. |
| 02/14/2025 | Date of the form filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.